

***Fiscal Year 2023 (FY23) Department of Defense Peer Reviewed Cancer Research Program (PRCRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Advancing Clinical Care Through Clinical Trials Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-ACCCT</a></p>	<p>Investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Preproposal required; application submission is by <b>invitation only</b>.</li> <li>• Supports clinical trials that will progress to the next stage of study or improve the standard of care for individuals living with cancer.</li> <li>• Requires a clinical trial to advance previously completed preclinical research to the clinic.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>• Preliminary data are required.</li> <li>• Investigational New Drug/Investigational Device Exemption application required by application submission deadline.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$3 million (M)</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 25, 2023 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> September 27, 2023 11:59 p.m. ET</p>
<p><b>Career Development Award – Fellow Option</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-CDA</a></p>	<p><b>Principal Investigator (PI):</b> Independent investigators at or above the level of Research Assistant Professor or Instructor (or equivalent) and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.</p> <p><b>Career Guide:</b> Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research.</p>	<ul style="list-style-type: none"> <li>• <b>Letter of Intent is required.</b> An invitation to submit a full application is <b>not</b> required.</li> <li>• Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>• Preliminary data are not required.</li> <li>• <b>Clinical trials are not allowed.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$400,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>up to 3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> August 10, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Career Development Award – Resident Option</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-CDA</a></p>	<p><b>PI:</b> Early-career physician-scientist currently enrolled in an accredited medical education program.</p> <p><b>Career Guide:</b> Investigators at or above the level of Associate Professor (or equivalent); must be an experienced physician-scientist with a strong record of funding and publications.</p>	<ul style="list-style-type: none"> <li><b>Letter of Intent is required.</b> An invitation to submit a full application is <i>not</i> required.</li> <li>Supports early-career physician-scientists with mentorship to prepare for impactful clinical cancer research.</li> <li>The Resident must be able to show a level of protected time for research within a 1-to-2-year span from June 2024-2026 with respect to the proposed project.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>Preliminary data are not required.</li> <li><b>Clinical trials are not allowed.</b></li> </ul>	<p><b>Research Funding Level I:</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$200,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>The maximum period of performance is <b>1</b> year.</li> </ul> <p><b>Research Funding Level II:</b></p> <ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$400,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> August 10, 2023 11:59 p.m. ET</p>
<p><b>Patient Well-Being and Survivorship Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-PWSA</a></p>	<p>Independent investigator with a faculty-level appointment (or equivalent).</p>	<ul style="list-style-type: none"> <li><b>Letter of Intent is required.</b> An invitation to submit a full application is <i>not</i> required.</li> <li>Supports innovative research studies to advance studies in preservation of function (physical ability), quality of life, symptom management, resilience, relief from neurocognitive deficits, and support for psychosocial issues related to cancer diagnosis, treatment, and survivorship.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>Preliminary data are required.</li> <li><b>Pilot clinical trials are allowed.</b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1M</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> August 10, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-IA</a></p>	<p>Independent investigator with a faculty-level appointment (or equivalent).</p>	<ul style="list-style-type: none"> <li>Preproposal required; application submission is by <i>invitation only</i>.</li> <li>Supports innovative <i>basic research</i> that may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities.</li> <li>Emphasis on innovation.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>Preliminary data are not required.</li> <li><i>Clinical trials are not allowed.</i></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$400,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>up to 2</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 12, 2023 11:59 p.m. ET</p>
<p><b>Impact Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-IPA</a></p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application.</p>	<ul style="list-style-type: none"> <li>Preproposal required; application submission is by <i>invitation only</i>.</li> <li>Supports hypothesis-driven, high-impact research.</li> <li>Supports mature research projects that specifically focus on critical scientific or clinical cancer issues and have the potential to make a major near-term impact.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li><b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>Preliminary data are required.</li> <li><i>Clinical trials are allowed.</i></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1M</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 12, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Translational Team Science Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-PRCRP-TTSA</a></p>	<p>At least two and a maximum of three PIs (at the level of Assistant Professor or equivalent) must partner in one overarching correlative or translational research study. Post-doctoral fellows cannot be named as a partnering PI.</p> <p>At least one of the PIs is encouraged to be a military or U.S. Department of Veterans Affairs investigator.</p>	<ul style="list-style-type: none"> <li>• <b>Letter of Intent is required.</b> An invitation to submit a full application is <b>not</b> required.</li> <li>• Emphasizes multi-PI, multidisciplinary collaborations.</li> <li>• Supports advanced translational studies that are based on results from clinical investigations and to utilize information from the clinical trials for research that would then inform the clinic.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Topic Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Military Health Focus Areas.</li> <li>• <b>Must</b> address at least one of the FY23 PRCRP Overarching Challenges.</li> <li>• Preliminary data are required.</li> <li>• <b>Clinical trials are allowed.</b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$2.5M</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> July 25, 2023 5:00 p.m. ET</p> <p><b>Application:</b> August 10, 2023 11:59 p.m. ET</p>